AKT1 and cancer: Interestingly, Zhu K et al reported that CAFs enhance osimertinib resistance via MET/AKT/Snail signaling pathway, and inhibition of this pathway may overcome osimertinib resistance by targeting both CAFs and cancer cells 25.